Routine Extracorporeal Life Support in Infarct-Related Cardiogenic Shock: 1-Year Results of the ECLS-SHOCK Trial

Steffen Desch, Uwe Zeymer, Ibrahim Akin, Michael Behnes, Daniel Duerschmied, Tienush Rassaf, Amir Abbas Mahabadi, Ralf Lehmann, Ingo Eitel, Tobias Graf, Tim Seidler, Andreas Schuster, Tharusan Thevathasan, Carsten Skurk, Peter Clemmensen, Marcus Hennersdorf, Stephan Fichtlscherer, Ingo Voigt, Melchior Seyfarth, Stefan JohnSebastian Ewen, Axel Linke, Eike Tigges, Peter Nordbeck, Leonhard Bruch, Christian Jung, Jutta Franz, Philipp Lauten, Marko Noc, Georg Fuernau, Hans-Josef Feistritzer, Janine Pöss, Eva Kirchhof, Taoufik Ouarrak, Steffen Schneider, Anne Freund, Holger Thiele

Abstract

Extracorporeal life support (ECLS) has been increasingly used in the treatment of severe infarct-related cardiogenic shock in the last decade. The randomised ECLS-SHOCK trial demonstrated no benefit of early routine use on 30-day all-cause death. We herein present mid-term results. At 1-year follow-up, there were no significant differences in all-cause or cardiovascular mortality, neurologic outcome, recurrent myocardial infarction, repeat revascularisation and rehospitalisations for heart failure between ECLS and usual medical care.

OriginalspracheEnglisch
ZeitschriftEuropean Heart Journal
ISSN0195-668X
DOIs
PublikationsstatusElektronische Veröffentlichung vor Drucklegung - 02.09.2024

Fingerprint

Untersuchen Sie die Forschungsthemen von „Routine Extracorporeal Life Support in Infarct-Related Cardiogenic Shock: 1-Year Results of the ECLS-SHOCK Trial“. Zusammen bilden sie einen einzigartigen Fingerprint.

Zitieren